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One of the most common forms of muscular dystrophy, fascioscapulohumeral dystrophy (FSHD), is 
clinically characterized by the initial onset of weakness in the facial muscles, which progresses to 
muscles of the shoulder blade (scapula), upper arm (humerus) and ultimately the trunk and lower 
limbs. Two years ago, an international team of researchers, including the laboratory of Dr. Stephen 
Tapscott (Human Biology Division), discovered that FSHD is caused by the expression of a specific 
transcription factor, DUX4, in adult skeletal muscle (Lemmers et al., 2010; Snider et al., 2010). Two 
genetically distinct types of this disease (FSHD1 and FSHD2) result in clinically indistinguishable 
symptoms, yet previously, the researchers only understood how DUX4 was activated in FSHD1 
patients. In a recent paper by the same research team, Lemmers et al. (2012) now report how they 
successfully deciphered the corresponding mechanism of DUX4 activation for FSHD2. 
The enduring collaboration that led to this important advancement in understanding mechanisms of 
muscular dystrophy has involved, among others, Drs. Silvère van der Maarel and Richard Lemmers 
(Leiden University), Dr. Daniel Miller (University of Washington), Dr. Rabi Tawil (University of 
Rochester), and past and present members of the Tapscott Lab (including Dr. Lauren Snider, Dr. 
Galina Filippova and former graduate student Dr. Linda Geng). A major source of funding for this 
work has come from a Program Project Grant (P01) awarded by NIH’s National Institute of 
Neurological Disorders and Stroke. This grant has been headed by Dr. Tapscott and administered 
through the Fred Hutchinson Cancer Research Center. 
In earlier studies, the researchers found that DUX4 is normally expressed in the germline, where it 
activates gametogenic and early developmental genes (Snider et al., 2010; Geng et al., 2012). In 
contrast, DUX4 is epigenetically repressed in healthy somatic cells, including differentiated muscle 
tissue. Multiple copies of the DUX4 retrogene lie within a D4Z4 macrosatellite repeat array 
(composed of a tandemly repeated 3.3 kilobase DNA unit) that is located near one end of 
chromosome 4 (Chr 4). FSHD1 is caused by D4Z4 array contraction, which results in DNA 
hypomethylation and decreased repressive heterochromatin (i.e., chromatin relaxation) in this region 
of Chr 4. Healthy individuals have 11 to 100 D4Z4 repeat units, whereas individuals with FSHD1 
have fewer than 11 repeats. In all types of FSHD, chromatin relaxation makes the epigenetic  
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repression of DUX4 less efficient, resulting in variegated DUX4 expression in a subset of skeletal 
muscle nuclei. However, contraction of the D4Z4 array, by itself, does not cause FSHD. A tightly 
linked Chr 4 haplotype permissive of DUX4 expression is also required. This haplotype contains a 
DNA sequence variant distal to the last D4Z4 repeat that signals polyadenylation of DUX4 mRNA 
and stabilizes the mRNA. In individuals affected by either FSHD1 or FSHD2, the DUX4 transcription 
factor damages muscle by activating stem cell and germline genes, which are toxic to muscle cells, 
as well as β-defensin 3, which inhibits muscle cell differentiation (Geng et al., 2012). 
Though the release of DUX4 from epigenetic repression is most commonly caused by D4Z4 
contraction, a substantial number of people with contraction-independent FSDH are genetically 
diagnosed each year. Because people suffering from this second type of FSHD are also known to 
exhibit DNA hypomethylation and relaxed chromatin at the D4Z4 array, Lemmers et al. performed a 
pedigree analysis on several families with a history of FSHD2 (see figure). They did so to determine 
whether an epigenetic modifier of the D4Z4 array, located somewhere else in the genome, causes 
FSHD2 when combined with the FSHD-permissiveDUX4 allele. The researchers first measured 
D4Z4 hypomethylation in study participants and their unaffected relatives. They found that not only 
do FSHD2-affected individuals have much lower levels of D4Z4 methylation compared to the general 
population, but the hypomethylation-trait was present in some other family members as a genetic 
trait that was inherited independently from the FSHD-permissive Chr 4 haplotype. Next, the authors 
sequenced the exomes (i.e., the coding portions of all genes known to be expressed) of twelve 
individuals in seven families with the hypomethylation trait. This revealed rare mutations in one of 
the two copies of SMCHD1 on Chr 18 as the cause of the hypomethylation-trait in all but one family. 
All mutations in this gene were found to lower the amount of SMCHD1 protein produced in somatic 
cells substantially, suggesting that a single functional copy of SMCHD1 is 'haploinsufficient' and 
does not produce enough SMCHD1 protein to prevent DUX4 de-repression. Finally, using 
experimental gene knockdown with RNA interference, the researchers demonstrated that 
reducedSMCHD1 expression in muscle cells cultured from healthy individuals 
triggered DUX4 expression at levels matching those seen in individuals with FSHD2. Therefore, 
FSHD2 is caused by the independent inheritance of an FSHD-permissive Chr 4 haplotype (signaling 
polyadenylation of DUX4 mRNA) and rare variants in SMCHD1 that cause D4Z4 hypomethylation, 
neither of which by itself causes disease. 
This important study identifies SMCHD1 as an epigenetic modifier of the D4Z4 array and the causal 
genetic determinant of FSHD2. SMCHD1 is a member of the 'Structural Maintenance of  
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Chromosomes' (SMC) gene family. SMC genes code for proteins that regulate chromatin repression 
in a wide variety of organisms. SMCHD1 itself was first identified in mice, where mutations of this 
gene epigenetically influence the probability that the coat color gene agouti is expressed in different 
patches of skin, resulting in mice with mottled fur. Given the profound epigenetic effects 
of SMCHD1 in humans, mice and many other organisms, the authors suggest that we may 
find SMCHD1 to be a genetic modifier of other human diseases as well. 
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Image courtesy of Stephen Tapscott 
Idealized composite FSHD2 pedigree, showing 
independent segregation of a muscular dystrophy-
permissive D4Z4 allele (4A) and any of several mutated 
forms of the SMCHD1 gene (green outline), which 
segregate with D4Z4 CpG hypomethylation. Only 
individuals with digenic inheritance of both the FSHD-
permissive D4Z4 allele and a mutated SMCHD1 allele 
develop D4Z4 contraction-independent, type 2 FSHD 
(i.e., FSHD2). The 4B allele of the D4Z4 array is not 
permissive of FSHD. Rare subtypes of the 4A allele 
(marked with #) are also considered to be FSHD-
nonpermissive. 
